Phase II Study Evaluating Ivonescimab in Combination With Chemotherapy for First- and Second-line Treatment of Advanced or Metastatic Gastric and Gastroesophageal Adenocarcinoma Patients

The goal of this clinical trial is to evaluate the addition of ivonescimab to standard chemotherapy in patients with advanced or metastatic gastric and gastroesophageal adenocarcinoma. The main question it aims to answer is : Does the addition of ivonescimab increase the response to treatment ? Participants will visit the clinic every 2 weeks for checkups, treatment administration and tests for collection of adverse events.

开始日期2025-09-01

申办/合作机构

UNICANCER

[+1]

NCT05733689

/ Not yet recruiting临床1期IIT

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) - a Phase Ib Feasibility Trial

This is a phase 1b prospective, single arm, open-label trial determining the efficacy and feasibility of using a ctDNA assay (test) result to help guide neoadjuvant chemotherapy in subjects with Stage IB, II or Stage III adenocarcinoma of the stomach or gastroesophageal junction (GEA).

开始日期2025-06-01

申办/合作机构

University of California, Irvine

[+1]

NCT06845319

/ Not yet recruiting临床2期IIT

Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients With Cardiomyopathy or at an Elevated Risk of Cardiotoxicity (NeoCARD): A Response Adapted Single-arm Phase 2 Trial

This is a multi-institute, single-arm Phase II study to assess the efficacy of a 12-18-week neoadjuvant carboplatin, paclitaxel, and pembrolizumab (CPP) regimen in a response-adaptive manner for triple-negative breast cancer (TNBC) patients who are ineligible for anthracycline-based therapy due to underlying cardiac conditions.

开始日期2025-06-01

申办/合作机构

The Medical University of South Carolina

100 项与 Paclitaxel ceribate 相关的临床结果

登录后查看更多信息

100 项与 Paclitaxel ceribate 相关的转化医学

登录后查看更多信息

100 项与 Paclitaxel ceribate 相关的专利（医药）

登录后查看更多信息

项与 Paclitaxel ceribate 相关的文献（医药）

2003-08-01·European heart journal1区 · 医学

Contrast media as carriers for local drug delivery Successful inhibition of neointimal proliferation in the porcine coronary stent model

1区 · 医学

Article

作者: Scheller, Bruno ; Romeike, Bernd ; Bohm, Michael ; Speck, Ulrich ; Sovak, Milos ; Schmitt, Alexander ; Stoll, Hans-Peter

BACKGROUND:

Lipophilic taxanes can be dissolved in contrast media at significantly higher concentration than in saline. As contrast media have occasionally been observed to delineate the contour of coronary arteries for some seconds they may serve as a matrix for an antiproliferative drug aimed at preventing restenosis. The aim of this study was to test a novel taxane-contrast agent formulation for this new approach in the setting of coronary stenting.

METHODS AND RESULTS:

In cell culture experiments (bovine vascular smooth muscle cells), 60-min incubation with contrast agent-taxane formulations (iopromide-paclitaxel, iopromide-protaxel) induced a significant, concentration-dependent inhibition of vascular smooth muscle cell (VSMC) proliferation over 12 days. Shorter incubation times of 10 and 3 min showed the same efficacy. For in vivo investigation, 16 stents were implanted into the coronary arteries of eight pigs using a 1.3 to 1 overstretch ratio. A control group received iopromide 370 alone while the treatment group was injected with a iopromide-protaxel formulation at a dose of 74 micromol/l, which is far below protaxel levels inducing systemic toxicity. Quantitative angiography and histomorphometry of the stented arteries asserted statistic equality of the baseline parameters between the control and treatment groups. After 28 days, the treatment group showed a marked reduction of the parameters characterizing in-stent restenosis, especially a 34% reduction of the neointimal area.

CONCLUSIONS:

First evidence is provided that using a contrast agent as solvent for a taxane constitutes a new drug delivery mechanism able to inhibit in-stent restenosis in the porcine restenosis model.

2002-01-01·Investigative radiology1区 · 医学

Acute Cardiac Tolerance of Current Contrast Media and the New Taxane Protaxel Using Iopromide as Carrier During Porcine Coronary Angiography and Stenting

1区 · 医学

Article

作者: Scheller, Bruno ; Clauss, Wolfram ; Bohm, Michael ; Speck, Ulrich ; Sovak, Milos ; Stoll, Hans-Peter ; Schmitt, Alexander

RATIONALE AND OBJECTIVES:

The systemic tolerance thresholds of modern low-osmolar x-ray contrast media (CM) are similarly high, but their effects on the cardiovascular system and on the coagulation differ. The aim of this study was to comparatively evaluate the cardiovascular tolerability of iopromide, ioxaglate, and iosmin, and of a novel taxane protaxel, dissolved in iopromide, as a carrier, by coronary angiography and stenting.

METHODS:

Sixteen pigs were randomized into four groups: iosmin (350 mg iodine/mL, n = 4, nonionic dimer), iopromide (370 mg iodine/mL, n = 4, nonionic monomer), ioxaglate (320 mg iodine/mL, n = 4, ionic dimer), and 70-micromol protaxel dissolved in iopromide 370 mg iodine/mL, intended to prevent restenosis. Coronary angiography was performed via the left carotid artery followed by implantation of stents into the left anterior descending and the circumflex arteries. About 80 mL per animal was used in each group.

RESULTS:

There were no thrombotic complications and no significant adverse events of electrocardiography, blood pressure, or contractility during or after CM injections. There were no differences among the CM tested except that ioxaglate was the only agent showing a significant reduction in dp/dt after 50 seconds compared to iosmin. The values of preinjection parameters were most rapidly regained after iosmin, compared with other CM tested.

CONCLUSIONS:

The novel iso-osmolar nonionic CM iosmin is well tolerated in porcine coronary angiography and subsequent stenting. The cardiac tolerance of iopromide has not been adversely affected by addition of the cytostatic protaxel.

2001-04-01·Anti-cancer drugs4区 · 医学

A new prodrug of paclitaxel: synthesis of Protaxel

4区 · 医学

Article

作者: Seligson, Allen L. ; Terry, Ronald C. ; Douglass, James G. III ; Sovak, Milos ; Bressi, Jerome C.

2' and 7 Polyol carbonates of paclitaxel were synthesized and screened as potential paclitaxel prodrugs. Paclitaxel is released from 7-(2",3"-dihydroxypropylcarbonato) paclitaxel (Protaxel) at rates inversely proportional to pH, by an intramolecular cyclization. Compared to paclitaxel, maximum tolerated i.v. or i.p. doses (MTD) of Protaxel are about 2.5- to 3-fold higher; its efficacy is substantially higher in human cancer line xenografts in athymic mice, especially in prostate PC-3, breast MDA-MB 468 and ovary OVCAR-1.

项与 Paclitaxel ceribate 相关的新闻（医药）

2025-04-04

·汇聚南药

沈阳药科大学药剂学团队在抗肿瘤前药纳米递释系统领域取得新进展

癌症治疗是全球医学亟待突破的重大挑战，小分子前药纳米组装体凭借其制备工艺简便、载药量高、可控的药物释放和无载体毒性等优势在癌症治疗领域展现出了广阔的发展前景。但是前药纳米组装体的合理设计仍是一项巨大的挑战。为此，沈阳药科大学无涯创新学院药剂学团队提出了前药纳米组装体的模块化设计概念，极大地加速了药物的优化进程与筛选效率。将药物模块与合适的修饰模块相连构建自组装型前药；在药物模块与修饰模块中间插入响应模块保证母药的智能释放；在前药纳米组装体的表面修饰表面功能化模块以改善其体内命运和肿瘤靶向性。在模块化设计中，修饰模块在驱动前药稳定组装方面发挥着重要作用。修饰模块的结构和性质会显著影响前药的分子间作用力，以及前药与表面功能化模块的亲和力，进而调节前药纳米组装体的组装、激活和体内命运。鉴于此，本团队深入探究了修饰模块的多个核心属性，包括亲疏水性、碳链长度以及刚柔性等，以期进一步优化前药纳米组装体的性能，为抗癌领域带来更为高效、精准的治疗策略。分别开展如下工作：研究工作一：研究团队首先探究了修饰模块的长度对前药纳米组装体的影响，以紫杉醇（PTX）为药物模块，以二硫键为响应模块，不同碳链长度（AC12，AC16，AC20，和AC24）的脂肪醇作为修饰模块，构建了4种紫杉醇前药。研究发现，随着碳链长度（AC12，AC16，AC20）的增加，紫杉醇前药间的疏水作用力不断增强，导致其自组装能力逐渐增强。但是，当链长进一步增加到AC24时，前药的疏水作用力过强会导致前药聚集沉淀。同时，碳链长度还会进一步影响前药纳米组装体的释药速率、抗肿瘤活性和耐受性。碳链长度最短的PTX-AC12前药纳米组装体具有最强的氧化还原敏感性，释放PTX的速度最快，细胞毒性最强。但是，血液中的氧化物质导致其在体循环中提前释放出PTX，药动学性质不佳。碳链长度最长的PTX-AC24前药纳米组装体显著改善PTX的药动学行为，但过强的疏水性限制其在肿瘤部位智能激活，导致其抗肿瘤活性不佳。PTX-AC16和PTX-AC20前药纳米组装体则表现出适中的氧化还原敏感性、有效的抗肿瘤活性和良好的耐受性。特别是PTX-AC20前药纳米组装体还表现出优越的自组装能力和较长的体内滞留时间，这为解决化疗药物的疗效和耐受性的矛盾带来了新思路。总的来说，本研究探索了修饰模块中脂肪醇的碳链长度对前药纳米组装体体内外命运的影响，并强调了优化修饰模块的长度在前药纳米组装体合理设计中的重要性。相关研究工作发表在《Journal of Controlled Release》（IF=10.5），题为“Exploring the optimal chain length of modification module in disulfide bond bridged paclitaxel prodrug nanoassemblies for breast tumor treatment”。无涯创新学院2023级博士研究生王丹平和硕士毕业生黄乐童为本文第一作者，孙进教授、孙丙军教授和师资博士后刘钿为本文通讯作者。研究工作二：通过前面的研究工作，我们发现修饰模块的碳链过短，可能会导致前药的组装稳定性不佳，从而影响其药动学行为；修饰模块的碳链过长则会降低前药的激活效率，导致药效不佳。因此，单纯优化修饰模块的长度难以有效解决这一矛盾问题。研究团队通过进一步文献调研发现，亲水性乙二醇片段可以作为氢键的供体或受体，与水分子形成氢键。那么将乙二醇结构引入修饰模块能否在提高前药组装能力的同时进一步促进相邻化学键的水解，从而实现前药的高效激活？这一问题有待进一步探究。在这项研究中，研究团队以紫杉醇（PTX）为药物模块，以二硫键为响应模块，乙二醇-油酸作为修饰模块，合成了PTX-SS-OA前药，并以不含乙二醇片段的PTX-SS-OAL前药为对照，深入探究了亲水性乙二醇片段对前药组装性能、药物释放行为和抗肿瘤效果的重要影响。结果表明，亲水性乙二醇片段的引入影响了前药的分子间作用力，增加了前药分子间的氢键作用。此外，亲水性乙二醇片段显著改善了氧化还原药物释放行为，从而进一步影响前药纳米组装体的治疗指数。含有亲水性乙二醇片段的PTX-SS-OA NPs表现出更强的氧化还原敏感性、细胞毒性和抗肿瘤效果。相比之下，尽管不含亲水性乙二醇片段的PTX-SS-OAL NPs的耐受性更好，但其氧化还原敏感性和细胞毒性较弱。这一研究表明亲水性乙二醇片段是调节前药纳米组装体治疗指数的关键因素，探索乙二醇等亲水性片段在药物递送系统中的合理应用，对于开发高效的前药纳米给药系统具有重要意义。相关研究工作发表在《ACS Central Science》（IF=13.1），题为“Hydrophilic Ethylene Glycol Fragments: A Determinant Affecting the Therapeutic Index of Paclitaxel Prodrug Nanoassemblies”。无涯创新学院2024级博士研究生李雅琪和师资博士后孙一鑫为本文第一作者，孙丙军教授和何仲贵教授为本文通讯作者。研究工作三：研究团队进一步探究了修饰模块的结构柔韧性对前药纳米组装体的影响。在结构上，修饰模块可被区分为块状和链状两大类，分别以甾醇和脂肪醇为例，两者展现出截然不同的特征：块状模块以其显著的高位阻刚性结构为标志，而链状模块则以其低位阻的柔性链著称。我们推测，柔性支链脂肪醇侧链能更有效地打破前药分子的紧密排列，从而增强其自组装能力。因此，本研究以氧化敏感的硫醚键为响应模块设计了两种灵活度不同的吉西他滨前药纳米组装体（CLS-S-GEM NPs和OD-S-GEM NPs），分别选用刚性结构胆固醇（CLS）和柔性结构2-辛烷基-1-十二醇（OD）作为修饰模块，系统性地考察了修饰模块的灵活度差异对前药纳米组装体构效关系的影响，解析了不同前药纳米组装体在自组装能力、氧化响应释药、体内命运和抗肿瘤疗效等方面的差异。结果显示，OD-S-GEM具有较强的自组装能力，其纳米组装体展现出了更强的胶体稳定性、母药激活效率和细胞摄取效率，进而对药代动力学和抗肿瘤效果产生了积极影响。体内实验表明，OD-S-GEM NPs在肿瘤部位的有效蓄积和智能释放是其发挥抗肿瘤功效的关键。一方面，OD-S-GEM NPs能够显著改善Cmax和AUC，从而保持了纳米组装体在血流中的结构完整性，并因其更好的稳定性和肿瘤细胞摄取能力而展示出更高的肿瘤蓄积；另一方面，OD-S-GEM NPs因其高氧化敏感性和快速释放特性，在两种小鼠肿瘤模型中展现出与吉西他滨溶液剂相当甚至更优的抗肿瘤疗效。总体而言，本研究强调了修饰模块结构柔韧性对前药纳米组装体的影响。相关研究工作发表在《Journal of Colloid And Interface Science》（IF=9.4），题为“Revealing the Impact of Modified Modules Flexibility on Gemcitabine Prodrug Nanoassemblies for Effective Cancer Therapy”。无涯创新学院2023级硕士研究生郭嘉煜、硕士毕业生张笑笑和博士毕业生董付丹为本文第一作者，孙丙军教授和姜琪坤特聘教授为本文通讯作者。研究工作四：与前面构建的以紫杉醇和吉西他滨为药物模块的前药纳米组装体有所不同，蒽环类抗肿瘤药物的结构中通常含有带正电荷的氨基，使得其自组装形成表面带正电荷的纳米组装体，导致其在血液循环中易被吞噬清除。因此，利用带有负电荷的表面功能化模块对带有正电荷的前药纳米组装体进行修饰，有望延长其血液循环时间。在众多带负电荷的载体材料中，胆固醇衍生物是经胆固醇分子修饰或代谢产生的化合物，具有良好的生物相容性。其结构上通常含有疏水的甾体结构以及带负电荷的硫酸基团或羧酸基团，具有较强的疏水性。然而，具有一定亲水性的蒽环类药物与疏水性的胆固醇衍生物仅通过静电作用力难以形成稳定的纳米组装体。因此，增强带正电荷药物的疏水性有望进一步提高两者之间的亲和性，进而提高前药纳米组装体的稳定性。基于此，研究团队利用酸敏感酰腙键（响应模块）将阿霉素（DOX）与疏水性的肉豆蔻酸（修饰模块）相连构建阿霉素前药（DOX-C14），以提高阿霉素的疏水性。进一步将DOX-C14与6种带有负电荷的胆固醇衍生物以不同摩尔比共组装，以筛选最优的阿霉素前药纳米组装体。结果表明，在静电作用和疏水作用下，DOX-C14与胆固醇硫酸钠以摩尔比1:2（DOX-C14-SCS (1:2)）和1:3（DOX-C14-SCS (1:3)）的比例所形成的纳米组装体的制剂学性质最好。随后，我们分别利用DSPE-PEG2k或CHOL-PEG2k对DOX-C14-SCS (1:2)和DOX-C14-SCS (1:3)进行表面修饰，进一步提高前药纳米组装体的稳定性和药动学行为。所制得的前药纳米组装体能够有效的蓄积在肿瘤部位，并在肿瘤酸性微环境的刺激下释放DOX发挥抗肿瘤作用。即使在非常高的剂量下（相当于10 mg/kg DOX），对正常组织也没有明显的毒性，显示出较好的肿瘤选择性。相关研究工作发表在《Chemical Engineering Journal》（IF=13.4），题为“Optimizing the stable doxorubicin prodrug nanocomplex for efficient and selective cancer therapy”。无涯创新学院2022级硕士研究生肖红英为本文第一作者，孙丙军教授、丁怀伟教授和师资博士后李凌霄为本文通讯作者。研究工作五：在上一项研究工作中，我们发现胆固醇硫酸钠作为表面功能化模块可以显著改善阿霉素前药纳米组装体的稳定性和体内外命运。在本项工作中，研究团队进一步利用疏水性的脂肪醇作为修饰模块与米托蒽醌偶联，提高其与疏水性胆固醇硫酸钠的亲和性，并深入探索修饰模块的链长对米托蒽醌前药与胆固醇硫酸钠亲和力的影响以构建稳定的前药纳米组装体。研究团队通过二硫键将米托蒽醌（MTO）分别与八醇（C8）、十二醇（C12）和十六醇（C16）连接，合成了不同碳链长度脂肪醇修饰的米托蒽醌前药。通过探头超声法制备米托蒽醌前药-胆固醇硫酸钠纳米组装体，并进行了处方筛选和优化。结果表明，与米托蒽醌相比，米托蒽醌前药显著提高了与胆固醇硫酸钠的亲和力。此外，在设计的三种米托蒽醌脂肪醇前药中，脂肪醇的碳链长度越长，其与胆固醇硫酸钠的亲和力越强，与胆固醇硫酸钠组装形成的纳米组装体越稳定，进而改善了米托蒽醌的递送效率。在到达肿瘤部位后，米托蒽醌前药纳米组装体能够被肿瘤细胞内高氧化还原态激活，从而发挥高效低毒的治疗作用。相关研究工作发表在《Science China Chemistry》（IF=10.4），题为“Sodium cholesterol sulfate mediated mitoxantrone prodrug electrostatic nanocomplexes: achieving the therapeutic efficacy and safety of mitoxantrone”。无涯创新学院2021级硕士毕业生赵二伟和师资博士后李凌霄为本文第一作者，孙丙军教授和何仲贵教授为本文通讯作者。喜欢我们文章的朋友点个“在看”和“赞”吧，不然微信推送规则改变，有可能每天都会错过我们哦~免责声明“汇聚南药”公众号所转载文章来源于其他公众号平台，主要目的在于分享行业相关知识，传递当前最新资讯。图片、文章版权均属于原作者所有，如有侵权，请在留言栏及时告知，我们会在24小时内删除相关信息。信息来源：沈阳药科大学往期推荐本平台不对转载文章的观点负责，文章所包含内容的准确性、可靠性或完整性提供任何明示暗示的保证。

核酸药物

2025-04-03

·ioncology

协同共振精准破局 | 郑敏教授：国创ADC“维迪西妥单抗+免疫”在妇科肿瘤中的突破与实践

点击蓝字关注我们2025年3月29日至3月30日，由广东省老年保健协会、广东省临床医学学会主办，中山大学肿瘤防治中心妇科承办的“第八届妇科肿瘤精准治疗暨广东省老年保健协会机器人妇科肿瘤专委会会议”在广州圆满落幕。本次会议邀请了国内相关领域的著名学者，围绕妇科肿瘤中的机器人手术、靶向治疗和免疫治疗等话题，共同探讨妇科肿瘤临床与科研领域的热点问题，为线上和线下的与会学者带来了一场高端的学术盛宴。近年来，免疫疗法、抗体偶联药物（ADC）等治疗手段的引入为妇科肿瘤精准治疗注入了新动力，亦是大会讨论热点话题之一。在此，《肿瘤瞭望》特邀中山大学肿瘤防治中心郑敏教授接受专访，分享下当前妇科肿瘤精准治疗领域以ADC为代表的创新疗法临床策略探索进展及实践现状。会议现场郑敏教授《肿瘤瞭望》：首先，请您结合临床实践现状，分享下您认为目前精准治疗策略在妇科肿瘤领域的实践面临哪些机遇与挑战，未来发展趋势如何？郑敏教授：妇科肿瘤严重威胁女性的生命健康，根据国际癌症研究机构2020年发布的数据，全球每年新增约133万例妇科恶性肿瘤患者，死亡约54万例[1]，而在我国，妇科恶性肿瘤已占女性恶性肿瘤的15%-20%，疾病负担十分沉重。其中，宫颈癌、卵巢癌和子宫内膜癌是三大常见的妇科恶性肿瘤。长期以来，对于妇科肿瘤的治疗以手术、放化疗为主，这些治疗手段对于早期患者来说疗效良好，但对于晚期患者，传统治疗手段疗效较差，患者生存亟待改善。许多患者在接受化疗后产生的耐药性，限制了化疗的长期疗效。此外，传统化疗药物的广泛细胞毒性不仅能消除肿瘤细胞，还会影响正常细胞，引起一系列副作用。近年来，随着对妇科肿瘤发生机制的深入理解以及基因组特征的更全面解析，免疫检查点抑制剂（ICIs）、抗体偶联药物（ADC）等新兴治疗手段的出现开启了妇科肿瘤精准治疗新时代，为更多妇科肿瘤患者提供新的治疗选择[2]。妇科肿瘤的治疗范式也随之发生了根本性变革，宫颈癌治疗领域，以ICIs为代表的免疫治疗与放化疗的联合应用为高危局部晚期宫颈癌（III-IVA 期）患者提供了一种新的标准治疗策略。此外，随着ICIs与ADC等新兴疗法的联合策略在转移性、持续性或复发性宫颈癌临床应用中展现了良好的治疗前景[3]。卵巢癌的治疗模式从传统的手术联合化疗转变为包含手术、化疗、靶向治疗和免疫治疗的多模式治疗，ADC的临床应用、维持治疗策略的优化、免疫治疗新靶点的发现及联合策略的探索，为卵巢癌特别是铂耐药性卵巢癌（PROC）患者的治疗提供了更为精准的治疗选择[4]。子宫内膜癌领域，对于晚期、转移性子宫内膜癌的一线治疗，免疫疗法联合化疗可显著改善患者的生存结局。此外，靶向治疗与免疫治疗联合策略在经治的晚期dMMR子宫内膜癌治疗中展现了良好前景。尽管近年妇科肿瘤精准治疗策略探索进展飞速，然而机遇与挑战并存，妇科肿瘤的高度异质性为精准治疗靶点选择增加了难度。此外，新型靶向药物和免疫治疗药物在妇科肿瘤中的应用仍存在局限性，耐药等问题仍无法避免。未来，通过多学科协作模式，为妇科肿瘤患者探索更加精准的治疗策略仍任重道远。《肿瘤瞭望》：在妇科肿瘤精准治疗探索历程中，“魔法子弹”ADC的出现，为妇科肿瘤带来了更加精准的靶向治疗策略，其中对于ADC药物获益患者群体的选择至关重要。请您结合临床实践经验及相关研究进展，谈谈您认为妇科肿瘤领域ADC药物治疗获益群体选择需从哪些方面考量？郑敏教授：的确，ADC药物通过不断优化药物设计、联合治疗策略以及精准筛选患者，为妇科肿瘤患者带来更好的疗效及预后。其中，精准筛选获益人群是决定治疗成功与否的关键。● 靶点选择ADC药物的成功主要依赖于对肿瘤细胞表面特定靶点的精准识别，因此选择合适的靶点表达患者人群对药物疗效至关重要。目前，妇科肿瘤领域ADC药物研发热门靶点包括HER2、Trop-2、FRα、TF等。其中，人类表皮生长因子受体2（HER-2）基因作为重要的生物标志物之一，在宫颈癌、子宫内膜癌和卵巢癌中均存在一定的蛋白高表达率或基因扩增率[5]。既往研究数据显示，中国妇科肿瘤患者中HER2表达率（IHC 1+、2+、3+）约为40%-50%，个人认为此数据相对保守，应用新鲜标本进行检测，HER2表达率可高达60%~70%。因此，HER-2基于其为妇科肿瘤重要不良预后因素之一，成为妇科肿瘤领域ADC药物开发重要靶点。维迪西妥单抗（RC48）作为首个获批上市的国产靶向HER2超级抗微管-ADC药物，RC48-C018临床研究显示，其在复发或转移性子宫颈癌患者中客观缓解率（ORR）达36.4%，12个月的总生存期（OS）率为66%，为HER2表达的妇科肿瘤患者，尤其是二线及以上治疗的患者，提供了一种全新有效的治疗选择。此外，值得一提的是，该研究结果可以看出，无论HER2免疫组化评分为1+、2+或3+的患者均能从维迪西妥单抗治疗中获益，展现了其广泛的适应性[6]。● 不良反应管理不同ADC药物的不良反应对获益人群的选择影响较大，如间质性肺病（ILD）或肺炎等不良反应或对老年、肺部基础病患者生存获益产生影响；眼部相关不良反应也应引起高度重视，需要谨慎处理、密切观察，在接受治疗前应进行相关检查以评估患者是否适用。然而，临床实际应用ADC药物时也发现，并非所有ADC药物均会发生严重不良反应。维迪西妥单抗（RC48）在RC48-C018临床研究中的安全性结果显示其整体安全性可耐受且可控，没有出现眼毒性、肺部毒性或致死性TRAEs。同时，在临床实践中亦发现，绝大多数患者耐受性良好，没有出现明显的不良反应。● 药物可及性近年来，创新药的医保准入不断提高了药品的可及性，维迪西妥单抗（RC48）作为我国首个获得美国FDA和中国药监局突破性疗法双重认定的ADC药物，已在我国获批用于胃癌和尿路上皮癌治疗，并纳入国家医保目录，可及性提升的同时，相较于同类进口药物一疗程20~30万的治疗费用，维迪西妥单抗一疗程治疗费用仅需几千元，极大程度减轻了患者经济负担，真正实现了“让优质国产创新药惠及更多中国患者”的社会价值。综上，ADC 药物（如 RC48）通过精准靶点选择、安全性优化及可及性提升，为妇科肿瘤患者提供了更高效、低毒性的治疗选择。《肿瘤瞭望》：近年来，“ADC+免疫”联合策略在妇科肿瘤领域探索相关研究成果展现了其良好的临床前景，成为领域探索热点。2024年IGCS大会上，您作为Leading PI在一项维迪西妥单抗（RC48）联合免疫治疗HER2表达的妇科肿瘤探索性临床研究ORR高达50%，令人印象深刻。请您分享一下以“ADC+免疫”为代表的“靶免联合”策略治疗妇科肿瘤的理论基础及突破性研究进展？郑敏教授：目前，对于复发转移性妇科恶性肿瘤患者，化疗等传统治疗手段疗效不加且预后较差，尽管ICIs及PARP抑制剂的出现改善了这部分患者的预后，但仍无法避免复发。因此，对于复发和转移性妇科恶性肿瘤患者亟需探索更有效且耐受性良好的新型治疗手段。● “ADC+免疫”联合策略治疗妇科肿瘤理论基础联合策略基于其可发挥不同治疗手段的协同效应，从而增强疗效的优势已成为妇科肿瘤治疗策略探索必要发展趋势。其中，ADC药物由靶向特异性抗原的单克隆抗体与小分子细胞毒性药物通过连接子链接而成，能够实现化疗药物在肿瘤部位的选择性递送，提高抗肿瘤疗效的同时，显著降低化疗相关毒性，其与免疫治疗策略联合应用成为妇科肿瘤领域具有临床潜力的研究热点。其作用机制主要包括如下：以维迪西妥单抗（RC48）为例，在RC48与ICIs联合应用中，首先，ICIs通过激活T细胞的免疫应答，增加肿瘤细胞的免疫原性，使肿瘤细胞更容易被免疫系统识别和清除。与RC48联合后，免疫系统可以协同发挥作用，从而提高抗肿瘤效应[7]。其次，RC48可通过细胞毒药物的释放能够破坏肿瘤微环境，促使更多的肿瘤抗原暴露，从而增强免疫系统的识别，增强免疫原性，进一步提升免疫治疗药物的效果[8]。此外，联合治疗有助于降低肿瘤细胞对单一治疗手段产生耐药性的风险。● AK001研究——“ADC+免疫”联合策略为HER2表达宫颈癌患者提供了更加精准的治疗选择由此，AK001研究应运而生，该研究旨在评估卡度尼利单抗联合维迪西妥单抗或白蛋白结合型紫杉醇在治疗复发或转移性宫颈癌的有效性及安全性（AK001）。该研究主要亮点在于，首先AK001研究的队列1纳入的患者均为HER2表达（IHC 1+、2+、3+）的复发或转移性宫颈癌患者，其中大部分为HER2低表达，50%的患者既往接受过PD-1/PD-L1免疫检查点抑制剂的治疗，这一比例与目前真实世界中的复发或转移性宫颈癌患者的治疗现状高度相符。其次，研究结果显示，尽管患者既往接受过化疗、PD-1/PD-L1免疫检查点抑制剂的治疗，接受卡度尼利单抗联合维迪西妥单抗治疗后，ORR仍高达50.0%，DCR达到80%。由此可见，“免疫双抗+ADC”的组合为既往已经使用过PD-1/PD-L1免疫检查点抑制剂的复发或转移性宫颈癌患者提供了一种新的二线及以后的治疗方案，为HER2表达的宫颈癌患者提供了更加精准的治疗选择[9]。《肿瘤瞭望》：维迪西妥单抗（RC48）作为第一个获批的国产靶向HER2的ADC药物，其单药及联合策略在妇科肿瘤治疗中的探索均展现了显著临床优势，请您为我们介绍一下您在临床实践中应用该联合策略的心得体会？您认为RC48联合免疫治疗临床实践前景如何？郑敏教授：目前，维迪西妥单抗联合免疫治疗已经在妇科恶性肿瘤患者后线治疗临床实践中显示了很好的疗效。● 病例1：患者女性，70岁，子宫颈癌四期（晚期），肺转移、全身多发淋巴结转移；就诊后收住入院，入院后该患者接受阿帕替尼联合化疗，疾病缓解持续1年多，原发病灶宫颈处放疗后，发生转移；随即接受双抗治疗×4，疗效评估PD；接受维迪西妥单抗+卡度尼利单抗×5后，CT评估病灶缩小；维迪西妥单抗+卡度尼利单抗×10后，CT评估病灶完全消除，获得CR。● 病例2：患者女性，40岁，卵巢透明细胞癌，胸腔、皮下、腹部及多处骨骼可见转移，既往接受贝伐珠单抗+化疗多个疗程后，PD。骨痛无法直立行走，接受曲马多镇痛疗效不佳；就诊后收住入院，入院后给予人血白蛋白，维迪西妥单抗+替雷利珠单抗×1，疼痛缓解；维迪西妥单抗+替雷利珠单抗×2，疾病缓解；随即接受维迪西妥单抗+替雷利珠单抗+卡铂+贝伐珠单抗×10，影像学评估疾病缓解持续11个月，患者可直立行走。● 病例3：患者女性，子宫内膜癌，骨髓抑制严重，全身浮肿，肠梗阻，既往多次接受化疗，PD；就诊后收住入院，腹腔镜探查术，病理活检，为HER2表达1+，接受维迪西妥单抗联合免疫治疗后，肿瘤标志物下降、影像学评估疾病缓解，持续治疗有望实现CR。综上，个人认为，维迪西妥单抗联合免疫治疗未来有望替代传统治疗、线数前移，为患者带来具有更好疗效及安全性的治疗选择。相关临床研究团队正在积极开展，期待获得好的临床数据，为维迪西妥单抗联合免疫治疗策略推向前线提供更有利的循证医学证据。总结ADC联合免疫疗法通过机制互补与协同增效，为妇科肿瘤患者提供了更精准、高效的治疗选择。维迪西妥单抗（RC48）凭借其靶点选择、安全性及可及性优势，与免疫治疗联合策略在妇科肿瘤治疗临床实践中展现了极大的临床潜力，未来有望线数前移，推动妇科肿瘤精准治疗进入“靶免联合”的新纪元。专家简介郑敏教授中山大学附属肿瘤医院妇科主任医师博士生导师博士后合作导师宫颈癌大PI中国抗癌协会第一届宫颈癌专业委员会委员华南肿瘤学国家重点实验室学术委员会委员广东省老年保健协会理事、机器人妇科肿瘤学分会主委广东省临床医学学会肿瘤学分会副主委广东省妇幼保健协会妇科肿瘤专业委员会副主委广东省健康管理协会妇科肿瘤专业委员会副主委广东省医学会机器人外科协会委员、妇科肿瘤学组副组长曾留学欧美近十年，取得瑞士苏黎世大学和伯尔尼大学双医学博士学位。主持多项国家自然科学基金面上项目及省,市重点项目研究，连续五次获得国自然科学基金面上项目资助在国内、国际知名期刊共发表98篇论文 (JCI, JAMA Oncology, et al)作为第一和/或通讯作者在Cell Reports Medicine, JITC, Theranostics, Cell death disease, Cancer等国际知名期刊发表56篇论文参考文献（上下滑动可查看）[1]首都医科大学肿瘤学系妇科肿瘤学组. 妇科常见恶性肿瘤全专结合管理专家共识[J]. 中国全科医学,2024.[2]Alberto, F., Daniela, M., Chiara, C., & Antonino, M. (2025) Perspectives, Challenges, and Advances in Therapeutic Strategies for Gynecological Malignant Tumors, Biomedicines, 13.2[3]Francoeur, A.A., Monk, B.J. & Tewari, K.S. Treatment advances across the cervical cancer spectrum. Nat Rev Clin Oncol 22, 182–199 (2025). [4]Choe, S.; Jeon, M.; Yoon, H. Advanced Therapeutic Approaches for Metastatic Ovarian Cancer. Cancers 2025, 17, 788.[5]张晗,刘继红,丁怡,等. 妇科恶性肿瘤抗HER-2治疗的研究进展[J].?中华妇产科杂志,2024,59(05)：410-416.[6]Guangwen, Y., Guiling, L., Qingshui, L., Youzhong, Z., Ruifang, A., Jinwei, M., Keqiang, Z., Hongying, Y., Yi, H., Ruixia, G., Li, S., An, L., Junying, T., Xiumin, L., Jianming, Y., Yun, L., Yanan, W., Haiwen, Z., Jianmin, F., & Lingying, W. (2024) Evaluation of the Effectiveness and Safety of Disitamab Vedotin in HER2-expressing 2L Recurrent or Metastatic Cervical Cancer (r/mcc): Interim Results of RC48-C018., Journal of Clinical Oncology, 42.16_suppl: 5528-5528.[7]Villacampa, G., Morgado, P.C., Carità, L., Navarro, V. (2024). Safety and efficacy of antibody-drug conjugates plus immunotherapy in solid tumors: A systematic review and meta-analysis. ScienceDirect, 58(4), 345-360.[8]Torres, E.T.R., Emens, L.A. (2022). Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies. Springer.[9]Haifeng, G., Jian, Z., Jianwei, W., Lili, L., Yun, Z., Baoyue, P., Weijun, Y., Li, Z., Yan, D., Jinxin, B., Xinping, C., & Min, Z. (2024) PT002/#568 Cadonilimab in Combination with Disitamab Vedotin or Nab-Paclitaxel in the Treatment of Recurrent or Metastatic Cervical Cancer: a Prospective, Double-Cohort, Multi-Center, Open-Label, Phase II Clinical Study (AK001), International Journal of Gynecological Cancer, 34: A23-A24.（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

抗体药物偶联物免疫疗法

2025-04-01

·GlobeNewswire-Health Care

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone, in patients with biliary tract cancer (BTC) treated in the second-line setting. The difference in ORR between the two treatment arms, the primary endpoint of the study, was statistically significant (p=0.031), and all responses have been confirmed by blinded independent central radiology review.The study also showed differences between treatment arms for other efficacy measures, including progressive disease (PD) rates of 16.2% in patients on tovecimig in combination with paclitaxel versus 42.1% in patients on paclitaxel alone.The pre-specified number of events required to trigger the analyses of the secondary endpoints, including progression free survival (PFS), overall survival (OS) and duration of response (DoR), has not yet been met due to fewer of these events occurring than were originally modeled. The Company expects to report these endpoints in Q4 of this year.Company to host webcast today, April 1, 2025 at 8:00 a.m. ET. BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, announced statistically significant top-line data on the primary efficacy endpoint for COMPANION-002, the Company’s ongoing Phase 2/3 randomized trial of tovecimig (formerly CTX-009) in combination with paclitaxel in patients with advanced BTC. "We are thrilled to share these positive primary endpoint data from the COMPANION-002 study of tovecimig in patients with advanced biliary tract cancer," said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. “We would like to thank all of the patients and their caregivers who have participated and continue to participate in this study. We believe these findings highlight the potential of tovecimig to provide a much-needed treatment option for the majority of patients with BTC who have limited alternatives after first-line therapy. We look forward to discussing these data with regulatory authorities." “As a treating clinician for over 20 years, I have seen firsthand how challenging a disease biliary tract cancer is. Patients currently have very limited treatment options, with the vast majority in the second-line setting having no approved therapeutic alternative whatsoever. For every statistic there is a person – a mother, father, relative, or friend – fighting for more time. Each investigative trial helps in this fight to advance new treatment options, and I look forward to following tovecimig’s continued progress,” said Juan Valle, MD, Chief Medical Officer of the Cholangiocarcinoma Foundation. Biliary tract cancer is estimated to affect approximately 23,000 patients annually in the United States. For the approximately 85% of patients with BTC whose tumors do not harbor an actionable mutation with an approved targeted therapy, there is currently no FDA-approved treatment in the second line setting. The combinations of therapeutics used in this setting, which are not labeled for this indication, generally have an ORR of ~5% or less and patients face a median overall survival of approximately six months. COMPANION-002 (tovecimig + paclitaxel versus paclitaxel alone): Top-Line Results The trial is a Phase 2/3 randomized, controlled study of tovecimig in patients with unresectable advanced, metastatic or recurrent biliary tract cancers who have received one prior systemic chemotherapy regimen. The study enrolled 168 adult patients, randomized in a 2:1 ratio to receive tovecimig plus paclitaxel (n=111) or paclitaxel alone (n=57). All patients were dosed with 80 mg/m2 of paclitaxel on days 1, 8 and 15 of every 28-day cycle. Patients in the tovecimig arm were also dosed with 10 mg/kg of tovecimig on days 1 and 15 of each 28-day cycle. The primary endpoint of the trial is ORR as confirmed by independent central radiology review and secondary endpoints include PFS, OS and DoR, among others. Patients in the paclitaxel-only arm who progressed could cross over to the tovecimig plus paclitaxel arm after centrally confirmed progression if they also still met the enrollment criteria for the study. Top-line results of the study are summarized below, and the Company expects to announce additional data, including key secondary endpoints, in Q4 2025: Primary Endpoint (ORR as confirmed by independent central radiology review). 17.1% ORR for tovecimig in combination with paclitaxel (19 of 111 patients) including one complete response, compared to 5.3% for paclitaxel alone (3 of 57 patients), in patients with BTC in the second line setting. This 11.8% relative improvement in ORR for those receiving the combination was statistically significant (p=0.031). Tovecimig +PaclitaxelPaclitaxelIntent-to-Treat Population n=111n=57Overall Response Rate (CR+PR)19 (17.1%)(p=0.031)3 (5.3%)BestOverall Responsen (%)Complete Response (CR)1 (0.9%)0 (0.0%)Partial Response (PR)18 (16.2%)3 (5.3%)Stable Disease (SD)49 (44.1%)19 (33.3%)Non-CR / Non-PD*9 (8.1%)2 (3.5%)Progressive Disease (PD)18 (16.2%)24 (42.1%)Not Evaluable (NE)**16 (14.4%)9 (15.8%) *Non-CR / Non-PD: patients enrolled based on local radiology scan results, but displayed no clearly definable target lesions as determined by independent central radiology. ** Not Evaluable: patients who did not receive a Week-8 scan. Secondary Endpoints. The COMPANION-002 study is ongoing and the data are not yet mature for the analyses of the secondary outcome measures (including PFS, OS and DoR). The trial requires a threshold of events in 80% of patients to trigger the secondary endpoint analyses. Based on current projections, the Company anticipates this pre-specified number of events to be reached in Q3 2025, and expects to report data from the secondary endpoints in Q4 2025.Safety & Tolerability. The safety profile of tovecimig in this study to date is consistent with prior studies of tovecimig. An independent Data Monitoring Committee (DMC) has reviewed safety data at four separate (pre-specified) DMC meetings and, after each meeting, recommended continuation of the study without modification. The Company expects to report detailed safety data with the analyses of secondary endpoints in Q4 2025. Webcast InformationCompass Therapeutics will host a webcast today, Tuesday, April 1, 2025 at 8:00a.m. ET to provide a review of the tovecimig top-line COMPANION-002 data. Interested parties may register for the call in advance via https://viavid.webcasts.com/starthere.jsp?ei=1712286&tp_key=3b05c5ebcd. A replay of the webcast will be available via the Investors section of the Compass website at investors.compasstherapeutics.com. About Tovecimig (CTX-009)Tovecimig is an investigational bispecific antibody that is designed to simultaneously blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization. Preclinical and early clinical data of tovecimig suggest that blockade of both pathways provides robust anti-tumor activity across several solid tumors, including colorectal, gastric, cholangiocarcinoma, pancreatic and non-small cell lung cancer. Partial responses to tovecimig as a monotherapy have been observed in heavily pre-treated patients with cancer who were resistant to approved anti-VEGF therapies. COMPANION-002, a Phase 2/3 trial of tovecimig plus paclitaxel versus paclitaxel monotherapy in patients with previously treated, unresectable advanced metastatic or recurrent biliary tract cancers (BTC) is ongoing (clinical trial information: NCT05506943). About Compass TherapeuticsCompass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The Company’s pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The Company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com. Forward-Looking StatementsThis press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding Compass’s product candidates, including the potential of tovecimig to provide a treatment option for patients with BTC in the second-line setting and the timing of announcement of key secondary endpoints in the COMPANION-002 trial. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, Compass’s ability to raise the additional funding it will need to continue to pursue its business and product development plans, the inherent uncertainties associated with developing product candidates and operating as a development stage company, Compass’s ability to identify additional product candidates for development, Compass’s ability to develop, complete clinical trials for, obtain approvals for and commercialize any of its product candidates, competition in the industry in which Compass operates and market conditions. These forward-looking statements are made as of the date of this press release, and Compass assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Compass files with the U.S. Securities and Exchange Commission (SEC) available at www.sec.gov, including without limitation Compass’s latest Annual Report on Form 10-K and subsequent filings with the SEC. Investor Contactir@compasstherapeutics.com Media Contact Anna Gifford, Chief of Staff media@compasstherapeutics.com617-500-8099

临床结果免疫疗法临床研究

100 项与 Paclitaxel ceribate 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤	临床1期	捷克	-	-
肿瘤	临床1期	-	Interpharma Praha as	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AACR2025	N/A	转移性乳腺癌 ctDNA ESR1 mutations	158	Paclitaxel-resistant group	餘窪製範膚廠選積鹹膚(積網廠艱選齋餘網繭積) = 網築淵蓋顧膚餘簾繭艱壓製積壓蓋選艱鏇觸範 (膚願鏇鹽鏇餘艱構範醖 )	积极	2025-04-28
				Paclitaxel-sensitive group	餘窪製範膚廠選積鹹膚(積網廠艱選齋餘網繭積) = 襯簾餘顧遞繭醖淵網簾壓製積壓蓋選艱鏇觸範 (膚願鏇鹽鏇餘艱構範醖 )
NCT03568422 (CTgov)	临床1/2期	HER2 阴性乳腺癌	37	Paclitaxel+CFI-402257	窪遞鹹鬱繭獵顧鹹齋構 = 憲顧顧製衊遞艱簾憲構顧觸獵餘願鏇憲醖鑰窪 (壓窪鏇壓醖願願夢遞製, 選餘網壓鑰壓獵範鹹鏇 ~ 繭醖獵鏇襯鬱膚鏇範獵)	-	2024-06-26
NCT03329378 (CTgov)	临床2期	局部晚期乳腺癌 \| 早期乳腺癌	7	Pertuzumab+Trastuzumab+Doxorubicin+cyclophosphamide+Paclitaxel (ddACTHP)	選艱鑰艱廠衊鹹憲壓網 = 餘憲鹹鹹製網醖簾醖網夢鑰蓋壓廠繭選構醖壓 (繭餘醖襯窪廠簾窪簾夢, 願膚選製鑰鑰繭鹹範築 ~ 築膚遞襯選築築鑰窪繭) 更多	-	2023-08-22
				Pertuzumab+Trastuzumab+Carboplatin+Paclitaxel+Docetaxel (TCHP)	選艱鑰艱廠衊鹹憲壓網 = 製網餘齋齋醖鏇製壓醖夢鑰蓋壓廠繭選構醖壓 (繭餘醖襯窪廠簾窪簾夢, 簾繭窪遞膚築積鹹觸鹽 ~ 淵繭廠醖顧衊獵襯壓艱) 更多
NCT01853748 (ATEMPT, CTgov)	临床2期	HER2阳性乳腺癌	512	Trastuzumab emtansine (Trastuzumab Emtansine (T-DM1))	構觸淵築願鬱艱獵餘鑰 = 憲觸築襯艱築襯鑰選憲積壓淵鬱膚壓齋築鹹鏇 (鏇觸鹹醖糧衊餘襯顧獵, 鹽願簾齋積廠選膚製積 ~ 憲衊積獵廠淵鹽蓋衊憲) 更多	-	2022-01-19
				Trastuzumab+Paclitaxel (Paclitaxel + Trastuzumab)	構觸淵築願鬱艱獵餘鑰 = 鏇鹽壓鑰範廠積窪遞鹹積壓淵鬱膚壓齋築鹹鏇 (鏇觸鹹醖糧衊餘襯顧獵, 壓獵壓築遞顧築構製蓋 ~ 齋構齋觸鏇鏇顧鹽蓋窪) 更多
NCT01796197 (PD3-08, CTgov)	临床2期	炎症性乳腺肿瘤 \| 淋巴结阳性乳腺癌 \| 乳腺癌 ... 更多	23	Mastectomy+Trastuzumab+cyclophosphamide+doxorubicin+Paclitaxel+pertuzumab	憲製憲繭鹹襯築壓簾獵 = 齋醖觸壓構鹽鬱淵顧鹹顧艱衊鏇衊蓋艱壓觸築 (廠壓醖艱積廠鹽膚遞築, 窪窪鑰積積憲襯觸艱顧 ~ 簾繭範鹽製顧齋窪壓鬱) 更多	-	2021-09-05
NCT00104676 (GETUG 13, CTgov)	临床3期	畸胎瘤 \| 非精原细胞生殖细胞肿瘤 \| 睾丸生殖细胞肿瘤	263	etoposide+cisplatin+bleomycin sulfate (Arm I)	構醖簾窪夢願衊選範膚 = 範願窪廠醖餘憲遞醖獵選憲蓋糧網鹹齋蓋醖網 (蓋膚糧襯襯網鏇窪蓋鏇, 顧衊鹽廠夢鹽獵襯遞衊 ~ 製齋築構襯蓋選衊鹽鹽) 更多	-	2021-06-07
				etoposide+ifosfamide+paclitaxel+cisplatin+oxaliplatin+bleomycin sulfate (Arm II)	構醖簾窪夢願衊選範膚 = 餘鏇鏇鬱製網構醖獵鬱選憲蓋糧網鹹齋蓋醖網 (蓋膚糧襯襯網鏇窪蓋鏇, 襯製憲製齋構夢觸鬱獵 ~ 構糧鏇範衊獵鑰鹹觸廠) 更多